Author/Authors :
Yamamoto, Kana Department of Reproductive - Developmental and Aging Sciences - Graduate School of Medicine - University of Tokyo, Tokyo, Japan , Ozaki, Akihiko Medical Governance Research Institute, Tokyo, Japan , Senoo, Yuki Medical Governance Research Institute, Tokyo, Japan , Sawano, Toyoaki Department of Surgery - Sendai City Medical Center, Miyagi, Japan , Tanimoto, Tetsuya Medical Governance Research Institute, Tokyo, Japan , Sah, Ranjit Tribhuvan University Institute of Medicine, Kathmandu, Nepal , Wang, Jiwei School of Public Health - Fudan University, Shanghai, China
Abstract :
The coronavirus disease 2019 (COVID-19) emerged in Wuhan, Hubei province, China, in November 2019, and spread to multiple countries, leading the World Health Organization (WHO) to declare it a pandemic on March 11, 2020. As of June 20, 2020, 8 766 887 cases and 462 706 deaths had been reported, with a case fatality rate (CFR) of 5.3% worldwide.1 While a crude CFR of COVID-19 in Japan was reportedly similar at 5.3% on June 20, 2020,1 the CFR reported from different regions of the world vary widely, partly due to differences in the healthcare capacity and thoroughness of the crisis response and extent and progress of the epidemic.2 Administration of real-time reverse transcription polymerase chain reaction (RT-PCR) testing for potential COVID-19 patients and their surveillance and tracking are considered as the key response.
Keywords :
Reverse-Transcriptase , Potential Implications , COVID-19 Pandemic , Diamond Princess
